Targeting Oncogenic miR-181a-2-3p Inhibits Growth and Suppresses Cisplatin Resistance of Gastric Cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.30620402
   PubMed Web of Science ®Google Scholar
• Colquhoun A, Arnold M, Ferlay J, Goodman KJ, Forman D, Soerjomataram I. Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut. 2015;64(12):1881–1888. doi:10.1136/gutjnl-2014-30891525748648
   PubMed Web of Science ®Google Scholar
• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–1403. doi:10.1016/j.ejca.2012.12.02723485231
   PubMed Web of Science ®Google Scholar
• Zong L, Abe M, Seto Y, Ji J. The challenge of screening for early gastric cancer in China. Lancet. 2016;388(10060):2606. doi:10.1016/S0140-6736(16)32226-727894662
   PubMed Web of Science ®Google Scholar
• Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378. doi:10.1016/j.ejphar.2014.07.02525058905
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297. doi:10.1016/S0092-8674(04)00045-514744438
   PubMed Web of Science ®Google Scholar
• Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 2008;111(3):478–486. doi:10.1016/j.ygyno.2008.08.01718823650
   PubMed Web of Science ®Google Scholar
• Yu ZW, Zhong LP, Ji T, Zhang P, Chen WT, Zhang CP. MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol. 2010;46(4):317–322. doi:10.1016/j.oraloncology.2010.02.00220219416
   PubMed Web of Science ®Google Scholar
• Goswami RS, Atenafu EG, Xuan Y, et al. MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma. J Clin Oncol. 2013;31(23):2903–2911. doi:10.1200/JCO.2012.45.305023835716
   PubMed Web of Science ®Google Scholar
• Hur K, Toiyama Y, Schetter AJ, et al. Identification of a metastasis-specific MicroRNA signature in human colorectal cancer. J Natl Cancer Inst. 2015;107(3). doi:10.1093/jnci/dju492
   PubMedGoogle Scholar
• Ueda T, Volinia S, Okumura H, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010;11(2):136–146. doi:10.1016/S1470-2045(09)70343-220022810
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol. 2012;81(2):103–122. doi:10.1016/j.critrevonc.2011.03.01021546262
   PubMed Web of Science ®Google Scholar
• Fang Y, Shen H, Li H, et al. miR-106a confers cisplatin resistance by regulating PTEN/Akt pathway in gastric cancer cells. Acta Biochim Biophys Sin. 2013;45(11):963–972. doi:10.1093/abbs/gmt10624108762
   PubMedGoogle Scholar
• Jin L, Ma XM, Wang TT, et al. Psoralen suppresses cisplatin-mediated resistance and induces apoptosis of gastric adenocarcinoma by disruption of the miR196a-HOXB7-HER2 axis. Cancer Manag Res. 2020;12:2803–2827. doi:10.2147/CMAR.S24809432368152
   PubMed Web of Science ®Google Scholar
• Jin L, Zhang N, Zhang Q, Ding G, Yang Z, Zhang Z. Serum microRNAs as potential new biomarkers for cisplatin resistance in gastric cancer patients. PeerJ. 2020;8:e8943. doi:10.7717/peerj.894332328349
   PubMed Web of Science ®Google Scholar
• Hong WS, Saijo N, Sasaki Y, et al. Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines. Int J Cancer. 1988;41(3):462–467. doi:10.1002/ijc.29104103253346112
   PubMed Web of Science ®Google Scholar
• Yu DS, Ma CP, Chang SY. Establishment and characterization of renal cell carcinoma cell lines with multidrug resistance. Urol Res. 2000;28(2):86–92. doi:10.1007/s00240005014310850629
   PubMedGoogle Scholar
• Choi H, Charnsangavej C, Faria SDC, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. Am J Roentgenol. 2004;183(6):1619–1628. doi:10.2214/ajr.183.6.0183161915547201
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu W, Ni P, Li A, Zhou J, Xu S. MiR-99a and MiR-491 regulate cisplatin resistance in human gastric cancer cells by targeting CAPNS1. Int J Biol Sci. 2016;12(12):1437–1447. doi:10.7150/ijbs.1652927994509
   PubMed Web of Science ®Google Scholar
• Anaya J. OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. PeerJ Comput Sci. 2016;2:e67. doi:10.7717/peerj-cs.67
   Web of Science ®Google Scholar
• Wong NW, Chen Y, Chen S, Wang X. OncomiR: an online resource for exploring pan-cancer microRNA dysregulation. Bioinformatics. 2018;34(4):713–715. doi:10.1093/bioinformatics/btx62729028907
   PubMed Web of Science ®Google Scholar
• Szász AM, Lánczky A, Nagy Á, et al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1065 patients. Oncotarget. 2016;7(31):49322–49333. doi:10.18632/oncotarget.1033727384994
   PubMedGoogle Scholar
• Nagy A, Lanczky A, Menyhart O, Gyorffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018;8(1):9227. doi:10.1038/s41598-018-27521-y29907753
   PubMed Web of Science ®Google Scholar
• Li T, Li D, Sha J, Sun P, Huang Y. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun. 2009;383(3):280–285. doi:10.1016/j.bbrc.2009.03.07719302977
   PubMed Web of Science ®Google Scholar
• Xia L, Zhang D, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer. 2008;123(2):372–379. doi:10.1002/ijc.2350118449891
   PubMed Web of Science ®Google Scholar
• Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008;68(2):425–433. doi:10.1158/0008-5472.CAN-07-248818199536
   PubMed Web of Science ®Google Scholar
• Yang SM, Huang C, Li XF, Yu MZ, He Y, Li J. miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology. 2013;306:162–168. doi:10.1016/j.tox.2013.02.01423466500
   PubMed Web of Science ®Google Scholar
• Jin L, Zhang Z. Serum miR-3180-3p and miR-124-3p may function as noninvasive biomarkers of cisplatin resistance in gastric cancer. Clin Lab. 2020;66(12). doi:10.7754/Clin.Lab.2020.200302
   Web of Science ®Google Scholar
• Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009;58(10):1375–1381. doi:10.1136/gut.2008.16781719201770
   PubMed Web of Science ®Google Scholar
• Chhabra R. let-7i-5p, miR-181a-2-3p and EGF/PI3K/SOX2 axis coordinate to maintain cancer stem cell population in cervical cancer. Sci Rep. 2018;8(1):7840. doi:10.1038/s41598-018-26292-w29777148
   PubMed Web of Science ®Google Scholar
• Khan IA, Rashid S, Singh N, et al. Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma. Sci Rep. 2021;11(1):2824. doi:10.1038/s41598-021-82266-533531550
   PubMed Web of Science ®Google Scholar